Potential benefits of icosapent ethyl on the lipid profile: Case studies

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The cardiovascular benefits of marine-derived omega-3 fatty acids are supported by epidemiologic and clinical studies. Both healthy patients and those with confirmed coronary heart disease are advised by the American Heart Association to consume omega-3 fatty acids either through dietary fatty fish or fish oil products. We present two case reports of patients with dyslipidemia who were switched from an omega-3 dietary supplement or a prescrip-tion omega-3 drug containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) to a new prescription EPA-only drug, icosapent ethyl (IPE). Products containing a combination of EPA and DHA, including dietary supplements and prescription products, are more likely to increase low-density lipoprotein cholesterol (LDL-C) levels compared with pure EPA-only products. The lipid profiles of these two patients were improved with IPE treatment, illustrating the potentially favorable effects of IPE compared with other products containing both EPA and DHA.

Original languageEnglish
Pages (from-to)13-15
Number of pages3
JournalClinical Medicine Insights: Cardiology
Volume8
DOIs
StatePublished - Feb 2 2014

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Lipids
Omega-3 Fatty Acids
Dietary Supplements
Prescriptions
Fish Products
Fish Oils
Dyslipidemias
Pharmaceutical Preparations
LDL Cholesterol
Coronary Disease
Epidemiologic Studies
Fishes
ethyl eicosapentaenoic acid

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{9abc28d2a95341f7bf00db76f3a545dd,
title = "Potential benefits of icosapent ethyl on the lipid profile: Case studies",
abstract = "The cardiovascular benefits of marine-derived omega-3 fatty acids are supported by epidemiologic and clinical studies. Both healthy patients and those with confirmed coronary heart disease are advised by the American Heart Association to consume omega-3 fatty acids either through dietary fatty fish or fish oil products. We present two case reports of patients with dyslipidemia who were switched from an omega-3 dietary supplement or a prescrip-tion omega-3 drug containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) to a new prescription EPA-only drug, icosapent ethyl (IPE). Products containing a combination of EPA and DHA, including dietary supplements and prescription products, are more likely to increase low-density lipoprotein cholesterol (LDL-C) levels compared with pure EPA-only products. The lipid profiles of these two patients were improved with IPE treatment, illustrating the potentially favorable effects of IPE compared with other products containing both EPA and DHA.",
author = "Hilleman, {Daniel E.} and Malesker, {Mark A.}",
year = "2014",
month = "2",
day = "2",
doi = "10.4137/CMC.s13571",
language = "English",
volume = "8",
pages = "13--15",
journal = "Clinical Medicine Insights: Cardiology",
issn = "1179-5468",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Potential benefits of icosapent ethyl on the lipid profile

T2 - Case studies

AU - Hilleman, Daniel E.

AU - Malesker, Mark A.

PY - 2014/2/2

Y1 - 2014/2/2

N2 - The cardiovascular benefits of marine-derived omega-3 fatty acids are supported by epidemiologic and clinical studies. Both healthy patients and those with confirmed coronary heart disease are advised by the American Heart Association to consume omega-3 fatty acids either through dietary fatty fish or fish oil products. We present two case reports of patients with dyslipidemia who were switched from an omega-3 dietary supplement or a prescrip-tion omega-3 drug containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) to a new prescription EPA-only drug, icosapent ethyl (IPE). Products containing a combination of EPA and DHA, including dietary supplements and prescription products, are more likely to increase low-density lipoprotein cholesterol (LDL-C) levels compared with pure EPA-only products. The lipid profiles of these two patients were improved with IPE treatment, illustrating the potentially favorable effects of IPE compared with other products containing both EPA and DHA.

AB - The cardiovascular benefits of marine-derived omega-3 fatty acids are supported by epidemiologic and clinical studies. Both healthy patients and those with confirmed coronary heart disease are advised by the American Heart Association to consume omega-3 fatty acids either through dietary fatty fish or fish oil products. We present two case reports of patients with dyslipidemia who were switched from an omega-3 dietary supplement or a prescrip-tion omega-3 drug containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) to a new prescription EPA-only drug, icosapent ethyl (IPE). Products containing a combination of EPA and DHA, including dietary supplements and prescription products, are more likely to increase low-density lipoprotein cholesterol (LDL-C) levels compared with pure EPA-only products. The lipid profiles of these two patients were improved with IPE treatment, illustrating the potentially favorable effects of IPE compared with other products containing both EPA and DHA.

UR - http://www.scopus.com/inward/record.url?scp=84893560587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893560587&partnerID=8YFLogxK

U2 - 10.4137/CMC.s13571

DO - 10.4137/CMC.s13571

M3 - Article

AN - SCOPUS:84893560587

VL - 8

SP - 13

EP - 15

JO - Clinical Medicine Insights: Cardiology

JF - Clinical Medicine Insights: Cardiology

SN - 1179-5468

ER -